ResearcherSecond Military Medical UniversityActive in the last 2 years

Lisi Peng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8891-782X; OpenAlex author ID A5014829233. Sources: OpenAlex.

Their work

Papers: 7
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 19

Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 7

Single-cell RNA sequencing reveals the process of CA19-9 production and dynamics of the immune microenvironment between CA19-9 (+) and CA19-9 (-) PDAC. Co-author DOI 10.1097/cm9.0000000000003130 ↗
The value of artificial intelligence techniques in predicting pancreatic ductal adenocarcinoma with EUS images: A meta-analysis and systematic review. Co-author DOI 10.4103/eus-d-21-00131 ↗
Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling Pathway. Co-author DOI 10.1007/s10620-021-07262-1 ↗
Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/aging.204221 ↗
Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo. Co-author DOI 10.1016/j.pan.2020.12.008 ↗
Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Score Formula in Pancreatic Ductal Adenocar… Co-author DOI 10.1155/2021/4986227 ↗
HPP1 gene promoter methylation in pancreatic cancer: correlation with carcinogenesis and clinical implication. Co-author PMID 31949740 ↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Haojie Huang · 3 shared papers, 2021–2024 · strength 0.46
Hua Yin · 3 shared papers, 2021–2023 · strength 0.44
Deyu Zhang · 3 shared papers, 2021–2023 · strength 0.44
Lu Zhuang · 3 shared papers, 2018–2022 · strength 0.35
Haojie Huang · 3 shared papers, 2018–2022 · strength 0.35
Zhaoshen Li · 2 shared papers, 2023–2024 · strength 0.35
- Paper Single-cell RNA sequencing reveals the process of CA19-9 production and dynamics of the immune microenvironment between… DOI 10.1097/cm9.0000000000003130 ↗
- Paper The value of artificial intelligence techniques in predicting pancreatic ductal adenocarcinoma with EUS images: A meta-… DOI 10.4103/eus-d-21-00131 ↗
Zhendong Jin · 2 shared papers, 2021–2022 · strength 0.27
- Paper Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma. DOI 10.18632/aging.204221 ↗
- Paper Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Sco… DOI 10.1155/2021/4986227 ↗
Yang Zhang · 2 shared papers, 2018–2022 · strength 0.24
- Paper Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling P… DOI 10.1007/s10620-021-07262-1 ↗
- Paper HPP1 gene promoter methylation in pancreatic cancer: correlation with carcinogenesis and clinical implication. PMID 31949740 ↗
Kun Lin · 2 shared papers, 2018–2022 · strength 0.24
- Paper Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling P… DOI 10.1007/s10620-021-07262-1 ↗
- Paper HPP1 gene promoter methylation in pancreatic cancer: correlation with carcinogenesis and clinical implication. PMID 31949740 ↗
Zhaoshen Li · 2 shared papers, 2018–2021 · strength 0.20
- Paper Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo. DOI 10.1016/j.pan.2020.12.008 ↗
- Paper HPP1 gene promoter methylation in pancreatic cancer: correlation with carcinogenesis and clinical implication. PMID 31949740 ↗
Kailian Zheng · 1 shared paper, 2024 · strength 0.18
- Paper Single-cell RNA sequencing reveals the process of CA19-9 production and dynamics of the immune microenvironment between… DOI 10.1097/cm9.0000000000003130 ↗
Deyu Zhang · 1 shared paper, 2024 · strength 0.18
- Paper Single-cell RNA sequencing reveals the process of CA19-9 production and dynamics of the immune microenvironment between… DOI 10.1097/cm9.0000000000003130 ↗
Shiyu Li · 1 shared paper, 2024 · strength 0.18
- Paper Single-cell RNA sequencing reveals the process of CA19-9 production and dynamics of the immune microenvironment between… DOI 10.1097/cm9.0000000000003130 ↗
Gang Jin · 1 shared paper, 2024 · strength 0.18
- Paper Single-cell RNA sequencing reveals the process of CA19-9 production and dynamics of the immune microenvironment between… DOI 10.1097/cm9.0000000000003130 ↗
Thiruvengadam Arumugam · 1 shared paper, 2021 · strength 0.11
- Paper Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo. DOI 10.1016/j.pan.2020.12.008 ↗
Hui Jiang · 1 shared paper, 2021 · strength 0.11
- Paper Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo. DOI 10.1016/j.pan.2020.12.008 ↗
Baoan Ji · 1 shared paper, 2021 · strength 0.11
- Paper Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo. DOI 10.1016/j.pan.2020.12.008 ↗
Craig D. Logsdon · 1 shared paper, 2021 · strength 0.11
- Paper Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo. DOI 10.1016/j.pan.2020.12.008 ↗
Kaixuan Wang · 1 shared paper, 2018 · strength 0.08
- Paper HPP1 gene promoter methylation in pancreatic cancer: correlation with carcinogenesis and clinical implication. PMID 31949740 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.